Buti, Sebastiano

A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable

Cortellini, A., Bersanelli, M., Buti, S., Cannita, K., Santini, D., Perrone, F., Giusti, R., Tiseo, M., Michiara, M., Di Marino, P., et al. (2019) · Journal for ImmunoTherapy of Cancer

Cancer Immunotherapy and BiomarkersCancer Risks and Factors

Cited by 413

Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program

on behalf of the Italian Nivolumab Renal Cell Cancer Early Access Program group, Verzoni, E., Cartenì, G., Cortesi, E., Giannarelli, D., De Giglio, A., Sabbatini, R., Buti, S., Rossetti, S., Cognetti, F., et al. (2019) · Journal for ImmunoTherapy of Cancer

Cancer Immunotherapy and BiomarkersRenal cell carcinoma treatment

Cited by 140

Combining PARP Inhibitors and Androgen Receptor Signalling Inhibitors in Metastatic Prostate Cancer: A Quantitative Synthesis and Meta-analysis

Messina, C., Giunta, E. F., Signori, A., Rebuzzi, S. E., Banna, G. L., Maniam, A., Buti, S., Cattrini, C., Fornarini, G., Bauckneht, M., et al. (2024) · European Urology Oncology

Prostate Cancer Treatment and ResearchPARP inhibition in cancer therapy

Cited by 39

LBA77 Fecal microbiota transplantation (FMT) versus placebo in patients receiving pembrolizumab plus axitinib for metastatic renal cell carcinoma: Preliminary results of the randomized phase II TACITO trial

Ciccarese, C., Porcari, S., Buti, S., Fornarini, G., Primi, F., Giudice, G. C., Damassi, A., Giron Berrios, J. R., Stumbo, L., Arduini, D., et al. (2024) · Annals of Oncology

Renal cell carcinoma treatmentCancer Immunotherapy and Biomarkers

Cited by 35